US 11,839,628 B2
Therapeutic detoxification compositions and methods of making and using same
Carol A Rae, Rapid City, SD (US); Jan Simoni, Rapid City, SD (US); Grace Simoni, Rapid City, SD (US); and John F. Moeller, Rapid City, SD (US)
Assigned to Immutrix Therapeutics, Inc., Rapid City, SD (US)
Filed by IMMUTRIX THERAPEUTICS, INC., Rapid City, SD (US)
Filed on Mar. 26, 2021, as Appl. No. 17/213,561.
Application 17/213,561 is a continuation of application No. 16/161,546, filed on Oct. 16, 2018, granted, now 10,960,022.
Application 16/161,546 is a continuation of application No. 15/500,893, granted, now 10,137,151, issued on Nov. 27, 2018, previously published as PCT/US2015/026373, filed on Apr. 17, 2015.
Claims priority of provisional application 61/981,061, filed on Apr. 17, 2014.
Prior Publication US 2021/0236543 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/44 (2006.01); A61M 1/36 (2006.01); B01J 47/026 (2017.01); A61K 9/14 (2006.01)
CPC A61K 33/44 (2013.01) [A61K 9/14 (2013.01); A61M 1/3679 (2013.01); B01J 47/026 (2013.01)] 13 Claims
 
1. A composition for use in treating an autoimmune disease where a first component comprises a first bimodal synthetic carbon particle mixture; a second component comprises a second bimodal synthetic carbon particle mixture and an anion exchange resin, wherein the second component has a weight ratio of the second bimodal synthetic carbon particle mixture to the anion exchange resin of from about 1:1 to about 5:2; and a third component comprises a cation exchange resin, wherein the first component, second component, and third component are separated but in fluid communication.